Alterity Therapeutics

Historical price data

Alterity Therapeutics is a clinical-stage biotechnology company dedicated to developing disease-modifying therapies for neurodegenerative diseases. Its core strategy leverages a proprietary platform of metal protein attenuating compounds (MPACs) to inhibit the aggregation of pathological proteins like alpha-synuclein. The company's lead asset, ATH434, is in Phase 2 clinical trials for Multiple System Atrophy (MSA) and Parkinson's disease, targeting a significant unmet medical need. As a publicly listed entity on the ASX, Alterity is advancing its pipeline through focused clinical execution and strategic capital management.

Proprietary platform of orally available, brain-penetrant metal protein attenuating compounds (MPACs) designed to inhibit pathological protein aggregation and reduce oxidative stress by modulating metal-protein interactions in the brain.

In MSA, ATH434's direct targeting of alpha-synuclein pathology is relatively unique in late-stage testing. In Parkinson's, its key differentiators are oral administration and a dual mechanism targeting protein aggregation and oxidative stress, setting it apart from infused biologics and other small molecules targeting specific genetic pathways.